Ablynx continues to rack up the deals for its potentially lucrative Nanobodies® and Merck Serono is the latest to enter into an agreement with the company. A flexible profit-sharing clause in the agreement could establish a steady revenue stream for Ablynx, though this will depend on whether the company chooses to exercise this.